Trial in progress: A phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecl... von Ghobadi, Armin, Budde, L Elizabeth, Galal, Ahmed, Stermer, Kristina, Austin, TaShara Lynn, Fan, Jean, DiPersio, John F.

Volltext

Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study von Cheng, Ann-Lii, Kang, Yoon-Koo, He, Aiwu Ruth, Lim, Ho Yeong, Ryoo, Baek-Yeol, Hung, Chao-Hung, Sheen, I-Shyan, Izumi, Namiki, Austin, TaShara, Wang, Qiang, Greenberg, Jonathan, Shiratori, Shinichi, Beckman, Robert A, Kudo, Masatoshi

Volltext

Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy‐naive p... von Forero‐Torres, Andres, Infante, Jeffrey R., Waterhouse, David, Wong, Lucas, Vickers, Selwyn, Arrowsmith, Edward, He, Aiwu Ruth, Hart, Lowell, Trent, David, Wade, James, Jin, Xiaoping, Wang, Qiang, Austin, TaShara, Rosen, Michael, Beckman, Robert, Roemeling, Reinhard, Greenberg, Jonathan, Saleh, Mansoor

Volltext

Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with ad... von Cheng, Ann-Lii, Kang, Yoon-Koo, Ryoo, Baek-Yeol, Yen, Chia-Jui, Lim, Ho Yeong, Oh, Do-Youn, Austin, TaShara, Wang, Qiang, Greenberg, Jonathan, Beckman, Robert A., Kudo, Masatoshi

Volltext